Study of Epratuzumab in Systemic Lupus Erythematosus

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety & efficacy of Epratuzumab with standard treatments for patients with SLE.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Epratuzumab

Criteria

Inclusion Criteria:

• Has SLE by ACR revised criteria (meets <4 criteria);

• Has SLE with at least one elevated lupus antibody;

• Has new onset of severe lupus disease flare in at least one body or organ system, excluding renal or neurologic

Exclusion Criteria:

• Active severe CNS or Renal disease defined by BILAG as Level A

• Allergy to murine or human antibodies

• Antiphospholid antibodies AND a history of thrombocytopenic events